Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Abstract
..
All quercetin studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   Meta Analysis       

Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase

Munafò et al., Research Square, doi:10.21203/rs.3.rs-1149846/v1
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
24th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
Lower risk for ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
In Vitro and In Silico study showing quercetin and luteolin inhibiting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).
Bioavailability. Quercetin has low bioavailability and studies typically use advanced formulations to improve bioavailability which may be required to reach therapeutic concentrations.
73 preclinical studies support the efficacy of quercetin for COVID-19:
45 In Silico studies1-45
22 In Vitro studies1,2,5,15,19,21,25,42,46-59
6 In Vivo animal studies5,19,52,55,60,61
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,3,9,10,22,24,25,30,38,39,41,42,62-64, MproB,3,7,9,11,13,15,17,18,20,23,24,30,34,36-38,42,43,45,63-65, RNA-dependent RNA polymeraseC,1,3,9,32,64, PLproD,3,37,45, ACE2E,22,23,28,37,41,63, TMPRSS2F,22, nucleocapsidG,3, helicaseH,3,29,34, endoribonucleaseI,39, NSP16/10J,6, cathepsin LK,26, Wnt-3L,22, FZDM,22, LRP6N,22, ezrinO,40, ADRPP,38, NRP1Q,41, EP300R,16, PTGS2S,23, HSP90AA1T,16,23, matrix metalloproteinase 9U,31, IL-6V,21,35, IL-10W,21, VEGFAX,35, and RELAY,35 proteins. In Vitro studies demonstrate inhibition of the MproB,15,46,51,59 protein, and inhibition of spike-ACE2 interactionZ,47. In Vitro studies demonstrate efficacy in Calu-3AA,50, A549AB,21, HEK293-ACE2+AC,58, Huh-7AD,25, Caco-2AE,49, Vero E6AF,19,42,49, mTECAG,52, and RAW264.7AH,52 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAI,55, db/db miceAJ,52,61, BALB/c miceAK,60, and rats66. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice60, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages5, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity54.
Important missing comments or errors? Let us know.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
i. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
j. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
k. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
l. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
m. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
n. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
o. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
p. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
q. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
r. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
s. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
t. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
u. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
v. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
w. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
x. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
y. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
z. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
aa. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ab. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ac. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ad. Huh-7 cells were derived from a liver tumor (hepatoma).
ae. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
af. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ag. mTEC is a mouse tubular epithelial cell line.
ah. RAW264.7 is a mouse macrophage cell line.
ai. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
aj. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
ak. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Munafò et al., 28 Dec 2021, preprint, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperQuercetinAll
Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase
Federico Munafò, Elisa Donati, Nicoletta Brindani, Giuliano Ottonello, Andrea Armirotti, Marco De Vivo
doi:10.21203/rs.3.rs-1149846/v1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global health pandemic. Among the viral proteins, RNA-dependent RNA polymerase (RdRp) is responsible for viral genome replication and has emerged as one of the most promising targets for pharmacological intervention against SARS-CoV-2. To this end, we experimentally tested luteolin and quercetin for their ability to inhibit the RdRp enzyme. These two compounds are ancestors of avonoid natural compounds known for a variety of basal pharmacological activities. Luteolin and quercetin returned a single-digit IC 50 of 4.6 µM and 6.9 µM, respectively. Then, through dynamic docking simulations, we identi ed possible binding modes of these compounds to a recently published cryo-EM structure of RdRp. Collectively, these data indicate that these two compounds are a valid starting point for further optimization and development of a new class of RdRp inhibitors to treat SARS-CoV-2 and potentially other viral infections.
Supporting Information. Supplementary gures reporting the: i) chromatography analysis of luteolin and quercetin (pages S2−S3), ii) chemical structures of luteolin and quercetin in different protonation states (page S4), iii) docking scores (page S5), iv) MD analysis (pages S6-S9). Supplementary Files This is a list of supplementary les associated with this preprint. Click to download.
References
Abian, Structural stability of SARS-CoV-2 3CLpro and identi cation of quercetin as an inhibitor by experimental screening, Int J Biol Macromol, doi:10.1016/j.ijbiomac.2020.07.235
Arencibia, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity, J Med Chem, doi:10.1021/acs.jmedchem.9b01760
Bayly, Cieplak, Cornell, Kollman, A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model, The Journal of Physical Chemistry, doi:10.1021/j100142a004
Bussi, Donadio, Parrinello, Canonical sampling through velocity rescaling, J Chem Phys, doi:10.1063/1.2408420
Carta, Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors, Bioorg Med Chem, doi:10.1016/j.bmc.2011.10.009
Casalino, AI-driven multiscale simulations illuminate mechanisms of SARS-CoV-2 spike dynamics, The International Journal of High Performance Computing Applications, doi:10.1177/10943420211006452
Chen, Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex, Cell, doi:10.1016/j.cell.2020.07.033
Chien, Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19, J Proteome Res, doi:10.1021/acs.jproteome.0c00392
Choudhry, Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), J Med Chem, doi:10.1021/acs.jmedchem.0c00626
De, Vivo, Cavalli, Recent advances in dynamic docking for drug discovery, WIREs Computational Molecular Science, doi:10.1002/wcms.1320
De, Vivo, Masetti, Bottegoni, Cavalli, Role of Molecular Dynamics and Related Methods in Drug Discovery, J Med Chem, doi:10.1021/acs.jmedchem.5b01684
Derosa, Ma Oli, D'angelo, Di Pierro, A role for quercetin in coronavirus disease 2019 (COVID-19), Phytother Res, doi:10.1002/ptr.6887
Deshmukh, Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease, Structure, doi:10.1016/j.str.2021.06.002
Friesner, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J Med Chem, doi:10.1021/jm0306430
Genna, Donati, De Vivo, The Catalytic Mechanism of DNA and RNA Polymerases, ACS Catalysis, doi:10.1021/acscatal.8b03363
Geronimo, Vidossich, Donati, Vivo, Computational investigations of polymerase enzymes: Structure, function, inhibition, and biotechnology, WIREs Computational Molecular Science, doi:10.1002/wcms.1534
Ghahremanpour, Identi cation of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2, ACS Med Chem Lett, doi:10.1021/acsmedchemlett.0c00521
Goris, Repositioning microbial biotechnology against COVID-19: the case of microbial production of avonoids, Microb Biotechnol, doi:10.1111/1751-7915.13675
Halgren, Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, J Med Chem, doi:10.1021/jm030644s
Hess, P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation, J Chem Theory Comput, doi:10.1021/ct700200b
Hillen, Structure of replicating SARS-CoV-2 polymerase, Nature, doi:10.1038/s41586-020-2368-8
Huang, Song, Huang, Sun, Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
Jockusch, A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19, Antiviral Res, doi:10.1016/j.antiviral.2020.104857
Joung, Cheatham, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations, J Phys Chem B, doi:10.1021/jp8001614
Khan, A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase, Int J Biol Macromol, doi:10.1016/j.ijbiomac.2021.03.112
Kokic, Mechanism of SARS-CoV-2 polymerase stalling by remdesivir, Nat Commun, doi:10.1038/s41467-020-20542-0
Lee, Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives, Bioorg Med Chem Lett, doi:10.1016/j.bmcl.2009.07.009
Li, De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov, doi:10.1038/d41573-020-00016-0
Liskova, Flavonoids against the SARS-CoV-2 induced in ammatory storm, Biomed Pharmacother, doi:10.1016/j.biopha.2021.111430
Maier, Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB, J Chem Theory Comput, doi:10.1021/acs.jctc.5b00255
Malone, Campbell, Molnupiravir: coding for catastrophe, Nat Struct Mol Biol, doi:10.1038/s41594-021-00657-8
Mishra, Rathore, RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2, J Biomol Struct Dyn, doi:10.1080/07391102.2021.1875886
Naydenova, Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2021946118
Newman, Cragg, Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019, J Nat Prod, doi:10.1021/acs.jnatprod.9b01285
Nguyen, Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris, Biotechnol Lett, doi:10.1007/s10529-011-0845-8
Ortega, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II alpha over beta, J Med Chem, doi:10.1021/acs.jmedchem.0c00774
Palermo, An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quanti ed by comparative analysis centered on the clinical candidate F14512, Chem Commun (Camb), doi:10.1039/c5cc05065k
Palermo, Favia, Convertino, De Vivo, The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition, ChemMedChem, doi:10.1002/cmdc.201500507
Parrinello, Rahman, Polymorphic transitions in single crystals: A new molecular dynamics method, Journal of Applied Physics, doi:10.1063/1.328693
Phillips, The coronavirus is here to stay -here's what that means, Nature, doi:10.1038/d41586-021-00396-2
Picarazzi, Vicenti, Saladini, Zazzi, Mori, Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge, Molecules, doi:10.3390/molecules25235695
Russo, Moccia, Spagnuolo, Tedesco, Russo, Roles of avonoids against coronavirus infection, Chem Biol Interact, doi:10.1016/j.cbi.2020.109211
Saeedi-Boroujeni, Mahmoudian-Sani, Anti-in ammatory potential of Quercetin in COVID-19 treatment, J In amm (Lond), doi:10.1186/s12950-021-00268-6
Shaldam, Yahya, Mohamed, Abdel-Daim, Al Naggar, In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes, Environ Sci Pollut Res Int, doi:10.1007/s11356-021-14195-9
Shang, Structural basis of receptor recognition by SARS-CoV-2, Nature, doi:10.1038/s41586-020-2179-y
Steinmann, Buer, Pietschmann, Steinmann, Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea, Br J Pharmacol, doi:10.1111/bph.12009
Tian, RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic, Eur J Med Chem, doi:10.1016/j.ejmech.2021.113201
Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, The Lancet, doi:10.1016/s0140-6736(20)31022-9
Wang, Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase, Cell, doi:10.1016/j.cell.2020.05.034
Wang, Wolf, Caldwell, Kollman, Case, Development and testing of a general amber force eld, J Comput Chem, doi:10.1002/jcc.20035
Wu, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3
Yan, Architecture of a SARS-CoV-2 mini replication and transcription complex, Nat Commun, doi:10.1038/s41467-020-19770-1
Yan, Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis, Cell, doi:10.1016/j.cell.2020.11.016
Yin, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science, doi:10.1126/science.abc1560
Yin, Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin, Nat Struct Mol Biol, doi:10.1038/s41594-021-00570-0
Zhang, Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations, ACS Cent Sci, doi:10.1021/acscentsci.1c00039
Zhao, Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2
Zhu, RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery, SLAS Discov, doi:10.1177/2472555220942123
{ 'institution': [{'name': 'Research Square'}], 'indexed': { 'date-parts': [[2021, 12, 29]], 'date-time': '2021-12-29T05:53:18Z', 'timestamp': 1640757198892}, 'posted': {'date-parts': [[2021, 12, 28]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T00:00:00Z', 'timestamp': 1640649600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2021, 12, 7]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly ' 'become a global health pandemic. Among the viral proteins, RNA-dependent RNA polymerase ' '(RdRp) is responsible for viral genome replication and has emerged as one of the most ' 'promising targets for pharmacological intervention against SARS-CoV-2. To this end, we ' 'experimentally tested luteolin and quercetin for their ability to inhibit the RdRp enzyme. ' 'These two compounds are ancestors of flavonoid natural compounds known for a variety of basal ' 'pharmacological activities. Luteolin and quercetin returned a single-digit ' 'IC<jats:sub>50</jats:sub> of 4.6 µM and 6.9 µM, respectively. Then, through dynamic docking ' 'simulations, we identified possible binding modes of these compounds to a recently published ' 'cryo-EM structure of RdRp. Collectively, these data indicate that these two compounds are a ' 'valid starting point for further optimization and development of a new class of RdRp ' 'inhibitors to treat SARS-CoV-2 and potentially other viral infections.</jats:p>', 'DOI': '10.21203/rs.3.rs-1149846/v1', 'type': 'posted-content', 'created': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T17:48:01Z', 'timestamp': 1640713681000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent ' 'RNA Polymerase'], 'prefix': '10.21203', 'author': [ { 'given': 'Federico', 'family': 'Munafò', 'sequence': 'first', 'affiliation': [{'name': 'Italian Institute of Technology'}]}, { 'given': 'Elisa', 'family': 'Donati', 'sequence': 'additional', 'affiliation': [{'name': 'Italian Institute of Technology'}]}, { 'given': 'Nicoletta', 'family': 'Brindani', 'sequence': 'additional', 'affiliation': [{'name': 'Italian Institute of Technology'}]}, { 'given': 'Giuliano', 'family': 'Ottonello', 'sequence': 'additional', 'affiliation': [{'name': 'Italian Institute of Technology'}]}, { 'given': 'Andrea', 'family': 'Armirotti', 'sequence': 'additional', 'affiliation': [{'name': 'Italian Institute of Technology'}]}, { 'given': 'Marco', 'family': 'De Vivo', 'sequence': 'additional', 'affiliation': [{'name': 'Italian Institute of Technology'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-1149846/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-1149846/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 28]], 'date-time': '2021-12-28T17:48:12Z', 'timestamp': 1640713692000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12, 28]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-1149846/v1', 'relation': {}, 'published': {'date-parts': [[2021, 12, 28]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0